U.S. March Manufacturing PMI Slightly Rises
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Source: seekingalpha
- PMI Overview: The U.S. March Manufacturing PMI stands at 52.7, slightly above the consensus of 52.3 and the previous value of 52.4, indicating a modest expansion in the manufacturing sector.
- Market Reaction: Despite the slight increase in PMI, the Chicago PMI fell more than expected in March, suggesting potential pressures on regional economic activity that could impact investor confidence.
- Composite PMI Trend: The composite PMI edged down in March, reflecting a slowdown in overall economic activity, as manufacturing growth could not fully offset weakness in the services sector, potentially influencing future economic policy decisions.
- Future Outlook: With the rise in manufacturing PMI, the market may closely monitor the Federal Reserve's monetary policy direction, particularly in balancing economic recovery against inflationary pressures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCYX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCYX
Wall Street analysts forecast SCYX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.668
Low
3.00
Averages
3.50
High
4.00
Current: 0.668
Low
3.00
Averages
3.50
High
4.00
No data
About SCYX
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SCYNEXIS Completes Acquisition of SCY-770 for ADPKD Treatment
- Acquisition Progress: SCYNEXIS has completed the acquisition of PXL-770, now known as SCY-770, a novel AMPK activator for treating autosomal dominant polycystic kidney disease (ADPKD), with a Phase 2 clinical trial expected to start in Q4 2026 and early efficacy results anticipated in H2 2027, highlighting the drug's potential in ADPKD treatment.
- Successful Financing: The company raised approximately $37.2 million in net proceeds through a private placement, significantly extending its cash runway to mid-2029, which will support the clinical development of SCY-770 and other projects.
- Clinical Trial Initiation: SCYNEXIS has dosed the first patient with the intravenous formulation of SCY-247 in a Phase 1 study, with topline data expected in Q3 2026, while also accepting requests for expanded access to oral SCY-247 to meet urgent patient needs.
- Financial Performance: As of Q1 2026, SCYNEXIS reported cash and cash equivalents totaling $72.4 million, an increase from $56.3 million at the end of 2025, with R&D expenses rising 140% year-over-year primarily due to costs associated with the SCY-770 acquisition, indicating the company's ongoing commitment to R&D investment.
See More
SCYNEXIS Approves Inducement Equity Awards for New VP
- Equity Award Approval: On April 30, 2026, SCYNEXIS's Compensation Committee approved inducement equity awards for a new Vice President, aimed at attracting the employee to join the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Stock Option Details: The awards include stock options for 125,000 shares of common stock at an exercise price of $0.93 per share, based on the closing price on April 30, 2026, reflecting the company's commitment to its new executive and confidence in future growth.
- Restricted Stock Units: Additionally, 20,000 restricted stock units (RSUs) were granted, which will vest in three equal annual installments over three years, further incentivizing the new executive's long-term service and contributions.
- Strategic Implications: This equity incentive plan not only demonstrates SCYNEXIS's focus on attracting talent but also aims to drive innovation in the treatment of rare diseases, particularly with the new therapy SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
See More
U.S. March Manufacturing PMI Slightly Rises
- PMI Overview: The U.S. March Manufacturing PMI stands at 52.7, slightly above the consensus of 52.3 and the previous value of 52.4, indicating a modest expansion in the manufacturing sector.
- Market Reaction: Despite the slight increase in PMI, the Chicago PMI fell more than expected in March, suggesting potential pressures on regional economic activity that could impact investor confidence.
- Composite PMI Trend: The composite PMI edged down in March, reflecting a slowdown in overall economic activity, as manufacturing growth could not fully offset weakness in the services sector, potentially influencing future economic policy decisions.
- Future Outlook: With the rise in manufacturing PMI, the market may closely monitor the Federal Reserve's monetary policy direction, particularly in balancing economic recovery against inflationary pressures.
See More
SCYNEXIS Secures $40M in Securities Purchase Agreement
- Financing Agreement Details: SCYNEXIS has entered into a securities purchase agreement with institutional investors, anticipating upfront gross proceeds of approximately $40M, with an additional $52.2M available if common warrants are fully exercised, indicating strong market confidence in its future.
- Share Issuance Plan: The company will issue 34.75M shares of common stock and 8.75M pre-funded warrants, along with common warrants for 43.5M shares, reflecting a proactive adjustment in its capital structure aimed at enhancing liquidity.
- Use of Proceeds: The net proceeds from this financing will be allocated for working capital and general corporate purposes, with estimates suggesting that these funds will support operations into mid-2029, ensuring ongoing investment in R&D and market expansion.
- Market Reaction: SCYNEXIS's stock rose 3.83% in pre-market trading to $0.82, reflecting positive investor sentiment towards the company's financing strategy and recognition of its growth potential.
See More
Scynexis Acquires Kidney Disease Treatment, Shares Surge
- Stock Surge: Scynexis, Inc. (SCYX) shares rose approximately 10% in pre-market trading on Tuesday, primarily driven by the announcement of a deal to acquire a potential kidney disease treatment from Poxel S.A.
- Acquisition Details: Scynexis signed a definitive agreement to acquire PXL-770, now renamed SCY-770, a novel oral therapy aimed at treating Autosomal Dominant Polycystic Kidney Disease, a leading cause of kidney failure.
- Clinical Trial Progress: The drug has demonstrated a favorable safety profile across eight clinical trials, with plans to initiate a Phase 2 study in late 2026 and early results expected in the second half of 2027.
- Funding Strategy: Scynexis expects to raise about $40 million upfront from a private placement, with the potential for an additional $52.2 million if all warrants are exercised for cash, thereby strengthening its financial position to support ongoing research and development.
See More
Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million
- Significant Transaction Value: Poxel SA has agreed to sell its drug candidate PXL770 to Scynexis for up to $196 million, including an upfront payment of $8 million and additional payments tied to development and commercial milestones, indicating strong market recognition of the drug's potential.
- Clinical Trial Plans: A Phase 2 proof-of-concept study for autosomal dominant polycystic kidney disease is expected to begin in Q4 2026, with initial efficacy results anticipated in the second half of 2027, which will provide critical data for further drug development.
- Focus on Core Pipeline: Poxel SA plans to concentrate on its core pipeline, including TWYMEEG and PXL065, while pursuing new partnerships to create long-term value, demonstrating a strategic emphasis on the ongoing advancement of drug development.
- Positive Market Reaction: Poxel SA's stock rose 9.78% to €0.2525 on the Paris Stock Exchange, while Scynexis saw a 4.76% increase to $0.8273 in pre-market trading on Nasdaq, reflecting investor optimism regarding the transaction.
See More
SCYNEXIS Completes Acquisition of SCY-770 for ADPKD Treatment
- Acquisition Progress: SCYNEXIS has completed the acquisition of PXL-770, now known as SCY-770, a novel AMPK activator for treating autosomal dominant polycystic kidney disease (ADPKD), with a Phase 2 clinical trial expected to start in Q4 2026 and early efficacy results anticipated in H2 2027, highlighting the drug's potential in ADPKD treatment.
- Successful Financing: The company raised approximately $37.2 million in net proceeds through a private placement, significantly extending its cash runway to mid-2029, which will support the clinical development of SCY-770 and other projects.
- Clinical Trial Initiation: SCYNEXIS has dosed the first patient with the intravenous formulation of SCY-247 in a Phase 1 study, with topline data expected in Q3 2026, while also accepting requests for expanded access to oral SCY-247 to meet urgent patient needs.
- Financial Performance: As of Q1 2026, SCYNEXIS reported cash and cash equivalents totaling $72.4 million, an increase from $56.3 million at the end of 2025, with R&D expenses rising 140% year-over-year primarily due to costs associated with the SCY-770 acquisition, indicating the company's ongoing commitment to R&D investment.
See More
SCYNEXIS Approves Inducement Equity Awards for New VP
- Equity Award Approval: On April 30, 2026, SCYNEXIS's Compensation Committee approved inducement equity awards for a new Vice President, aimed at attracting the employee to join the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Stock Option Details: The awards include stock options for 125,000 shares of common stock at an exercise price of $0.93 per share, based on the closing price on April 30, 2026, reflecting the company's commitment to its new executive and confidence in future growth.
- Restricted Stock Units: Additionally, 20,000 restricted stock units (RSUs) were granted, which will vest in three equal annual installments over three years, further incentivizing the new executive's long-term service and contributions.
- Strategic Implications: This equity incentive plan not only demonstrates SCYNEXIS's focus on attracting talent but also aims to drive innovation in the treatment of rare diseases, particularly with the new therapy SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
See More
U.S. March Manufacturing PMI Slightly Rises
- PMI Overview: The U.S. March Manufacturing PMI stands at 52.7, slightly above the consensus of 52.3 and the previous value of 52.4, indicating a modest expansion in the manufacturing sector.
- Market Reaction: Despite the slight increase in PMI, the Chicago PMI fell more than expected in March, suggesting potential pressures on regional economic activity that could impact investor confidence.
- Composite PMI Trend: The composite PMI edged down in March, reflecting a slowdown in overall economic activity, as manufacturing growth could not fully offset weakness in the services sector, potentially influencing future economic policy decisions.
- Future Outlook: With the rise in manufacturing PMI, the market may closely monitor the Federal Reserve's monetary policy direction, particularly in balancing economic recovery against inflationary pressures.
See More
SCYNEXIS Secures $40M in Securities Purchase Agreement
- Financing Agreement Details: SCYNEXIS has entered into a securities purchase agreement with institutional investors, anticipating upfront gross proceeds of approximately $40M, with an additional $52.2M available if common warrants are fully exercised, indicating strong market confidence in its future.
- Share Issuance Plan: The company will issue 34.75M shares of common stock and 8.75M pre-funded warrants, along with common warrants for 43.5M shares, reflecting a proactive adjustment in its capital structure aimed at enhancing liquidity.
- Use of Proceeds: The net proceeds from this financing will be allocated for working capital and general corporate purposes, with estimates suggesting that these funds will support operations into mid-2029, ensuring ongoing investment in R&D and market expansion.
- Market Reaction: SCYNEXIS's stock rose 3.83% in pre-market trading to $0.82, reflecting positive investor sentiment towards the company's financing strategy and recognition of its growth potential.
See More
Scynexis Acquires Kidney Disease Treatment, Shares Surge
- Stock Surge: Scynexis, Inc. (SCYX) shares rose approximately 10% in pre-market trading on Tuesday, primarily driven by the announcement of a deal to acquire a potential kidney disease treatment from Poxel S.A.
- Acquisition Details: Scynexis signed a definitive agreement to acquire PXL-770, now renamed SCY-770, a novel oral therapy aimed at treating Autosomal Dominant Polycystic Kidney Disease, a leading cause of kidney failure.
- Clinical Trial Progress: The drug has demonstrated a favorable safety profile across eight clinical trials, with plans to initiate a Phase 2 study in late 2026 and early results expected in the second half of 2027.
- Funding Strategy: Scynexis expects to raise about $40 million upfront from a private placement, with the potential for an additional $52.2 million if all warrants are exercised for cash, thereby strengthening its financial position to support ongoing research and development.
See More
Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million
- Significant Transaction Value: Poxel SA has agreed to sell its drug candidate PXL770 to Scynexis for up to $196 million, including an upfront payment of $8 million and additional payments tied to development and commercial milestones, indicating strong market recognition of the drug's potential.
- Clinical Trial Plans: A Phase 2 proof-of-concept study for autosomal dominant polycystic kidney disease is expected to begin in Q4 2026, with initial efficacy results anticipated in the second half of 2027, which will provide critical data for further drug development.
- Focus on Core Pipeline: Poxel SA plans to concentrate on its core pipeline, including TWYMEEG and PXL065, while pursuing new partnerships to create long-term value, demonstrating a strategic emphasis on the ongoing advancement of drug development.
- Positive Market Reaction: Poxel SA's stock rose 9.78% to €0.2525 on the Paris Stock Exchange, while Scynexis saw a 4.76% increase to $0.8273 in pre-market trading on Nasdaq, reflecting investor optimism regarding the transaction.
See More
